Stock Watch: Pfizer And Novo Nordisk Deliver Christmas Gifts Both Welcome And Unwanted

Either Way, Investors Hate Surprises

 
• By Andy Smith

While Pfizer’s analysts’ meeting cheered its investors with clear guidance, Novo Nordisk presented disappointing obesity data. The true value of CagriSema cannot be estimated without more information, however.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from R&D